Wednesday, July 7, 2010
This Week’s Feature
In Senate Testimony, AUL President Calls for Kagan Investigation
AUL President and CEO Dr. Charmaine Yoest last week made headlines as she testified before the Senate Judiciary Committee that not only should they reject Elena Kagan’s Supreme Court nomination, but they should also probe discrepancies between her written record and her committee testimony.
Dr. Yoest told the packed hearing room, “Based on our research, we believe that Ms. Kagan will be an agenda-driven justice on the Court, and that she will oppose even the most widely-accepted protections for unborn human life.”
Senators Jeff Sessions (R-Ala.) and Orrin Hatch (R-Utah) questioned Dr. Yoest closely about their concerns in light of the evidence she presented from AUL’s legal team that the nominee, who has a long history of abortion advocacy, had attempted to manipulate and politicize the medical opinions issued during the partial-birth abortion debate and on other issues of abortion-related law.
On The Docket
Sister Organization, AUL Action, asks Americans to Echo call for
Investigation
The partial-birth abortion scandal that is brewing around the Kagan nomination was the subject of an Action Alert sent out last week to grassroots activists around the country by AUL’s sister organization, AUL Action. The revelation that Elena Kagan, while serving in the Clinton White House, appeared willing to lobby not one, but two major medical organizations to change their positions on partial-birth abortion has caused deep concern here in Washington and around the country.
AUL Experts’ Commentary Featured on National Review Online & Human Events
Throughout the Kagan hearings, Dr. Yoest and other AUL experts kept pro-lifers abreast of the latest developments with their featured commentary on National Review Online’s Bench Memos and the Human Events blog.
In the News: AUL Warns that New Blood Test Would Lead to More Abortions
Fox News featured AUL Staff Counsel Mailee Smith last week in its story about an inexpensive medical test being prepared for the market, which would use a blood sample from a pregnant woman to detect whether her unborn child had Down Syndrome or other abnormalities. Smith told the network’s reporter, “If [the test] might more conclusively prevent false positives, it might have some benefit, but it will also likely lead to more abortions of children with disabilities.”
Advertisement
